Kornimate/medical-research-clean huggingface dataset:
methadone in ambulatory surgery

Conditions: Post-operative Pain; Anesthesia

Summary: the μ-opioid receptor agonist methadone is frequently used in adult anesthesia and adult pain therapy. methadone has an extremely long half-life, which confers therapeutic advantage by providing more stable plasma concentrations and long-lasting pain relief. methadone perioperative pharmacokinetics and effectiveness in perioperative pain relief in inpatients is well characterized. there is, however, no information on methadone use in an ambulatory surgery setting and outpatient procedures. this pilot investigation will determine effectiveness of intraoperative methadone in reducing postoperative opioid consumption and providing improved pain relief in patients undergoing moderately painful, ambulatory surgical procedures.


Eligibility criteria:
inclusion criteria: * age 18-65 years * undergoing general anesthesia and moderately painful, ambulatory surgical procedures with anticipated overnight, postop hospital stay of \< 24 hours * signed, written, informed consent exclusion criteria: * history of or known liver or kidney disease. * females who are pregnant or nursing. * opioid tolerant patients (e.g. preoperative methadone therapy or use of fentanyl transdermal patches) * history of allergy to methadone

Keywords: fentanyl, morphine methadone
magnesium supplementation for hypomagnesemia in chronic kidney disease

Conditions: Chronic Kidney Disease; Hypomagnesemia

Summary: randomized placebo-controlled interventional trial to investigate the effect of oral magnesium supplementation on intracellular magnesium in subjects with chronic kidney disease. we hypothesize that oral magnesium supplementation will increase intracellular magnesium in subjects with chronic kidney disease as well as increase serum magnesium.

chronic kidney disease (ckd) is associated with increase cardiovascular morbidity and mortality independent of traditional cardiovascular risk factors due to increased vascular calcification. epidemiological and experimental data suggest that hypermagnesemia and magnesium supplementation reduce vascular calcification in chronic kidney disease by increasing calcium/phosphate solubility in serum, by inhibiting calcium influx into vascular smooth muscle cells (vsmc), by inhibiting intracellular pro-calcification enzymes in vsmc and by increasing activity of intracellular anti-calcification enzymes in vsmc. a trial to investigate the effect of oral magnesium supplementation on vascular calcification in subjects with ckd is currently being planned, but prior to initiating such a trial it is necessary to determine the dose of oral magnesium needed to increase intracellular magnesium and serum magnesium.

Eligibility criteria:
inclusion criteria: * estimated glomerular filtration rate (egfr) \< 60 ml/min. * serum magnesium \< 0.82 mmol/l. * written informed consent. exclusion criteria: * hemodialysis. * peritoneal dialysis. * kidney transplant recipient. * parathyroid hormone \> 600 pg/l. * pregnancy. * comorbidity that makes study participation and completion impossible.

Keywords: chronic kidney disease hypomagnesemia
expanding ngs data with optical genome mapping (ogm)

Conditions: Neurodevelopmental Disorder (Diagnosis)

Summary: over 50% of pediatric neurological and neurodevelopmental disorders lack a molecular diagnosis after standard dna sequencing and molecular karyotyping. this is due to technical limitations, incomplete variant interpretation, and inadequate genotype-phenotype correlations. new sequencing technologies are crucial for clinical decision-making, offering complete profiles of variants in a patient's dna to personalize treatment. optical genome mapping (ogm) can detect nearly all structural variants in one experiment. this project aims to use ogm alongside ngs to improve diagnostic yield in 60 children with severe disorders who tested negative for ngs/cma.


Eligibility criteria:
inclusion criteria: * individuals without a molecular diagnosis (negative to es/cma analyses); * individuals with genetic diagnoses that explain only one component of their primary phenotype; * individuals carrying one or more variants of uncertain clinical significance * individuals with a phenotype highly reminiscent of clinically and molecularly well-defined syndromes (i.e., marfan syndrome) but negative to routine molecular analysis. exclusion criteria: * individuals who have not undergone initial diagnostic genetic tests (es/cma)

Keywords: optical genome mapping, neurodevelopmental disorders, genome sequencing
exploring pathology related to slowly expanding lesions using advanced imaging

Conditions: Multiple Sclerosis

Summary: this is an open, follow-up study to compare the performance of three critical imaging methods to detect chronic active lesions in multiple sclerosis (ms) in vivo.

smoldering inflammation is recognized as a critical contributor to ms progression-related central nervous system (cns) damage. activated microglia and macrophages particularly at chronic lesion edge are believed to promote lesion growth. reversing their harmful activity may prove to be an efficient way to halt progression independent of relapses in ms. these smoldering, or chronic active lesions can be detected in vivo using advanced imaging techniques. 1) specific algorithms can be used to identify lesion growth, with a hypothesis that the slowly evolving lesions (sel) are the ones harboring a rim of activated microglial cells, which contribute to damage in the surrounding tissue, and lesion growth. 2) lesions partially or entirely surrounded by rims of increased tissue intensity on qsm-mri (quantitative susceptibility mapping) sequences are considered as iron rim lesions, with iron-containing proinflammatory microglia/macrophages at the lesion edge. 3) in addition, 18 kda translocator protein-positron emission tomography (tspo-pet) imaging can be used to identify chronic active lesions based on tspo-expression by activated innate immune cells, and their gathering at the edges of chronic active lesions. the tspo-pet analysis of chronic active lesions can be semi-automated, and the specific radioligand binding at the chronic active lesion edge can be quantitated, which enhances the sensitivity of this method. despite existing preliminary data demonstrating increased qsm signal tspo-positive lesions, it is yet to be demonstrated how these three imaging methods perform in identifying chronic active lesions when compared to each other at larger scale.

Eligibility criteria:
inclusion criteria: * signing the informed consent form * ms diagnosis in accordance with mcdonald 2017 criteria * available longitudinal brain mr images (minimum 1 year) * simultaneous qsm mri sequence and tspo-pet * lesions with iron rim/s exclusion criteria: * patients with other neurodegenerative disease than ms * patients with other autoimmune disease than ms * patients with other significant or malignant underlying disease of any other organ system * patients that are pregnant or breast-feeding * corticosteroid treatment within 4 weeks of imaging * patients with significant abnormal findings other than ms in the screening mri * patients with claustrophobia, or a history of moderate to severe anxiety disorder or panic attacks (which could potentially lead to preterm termination of the imaging) * contraindication to pet scan investigations * exposure to experimental radiation in the past 12 months such that radiodosimetry limits would be exceeded by participating in this study * intolerance to previous pet scans; i.e. previous hypersensitivity reactions to any pet ligand or imaging agent or failure to participate in and comply with previous pet scans
dural puncture epidural technique versus conventional epidural techmique

Conditions: Gynecologic Disease Requiring Laparoscopic Hysterectomy Under Neuraxial Anesthesia

Summary: this study will be conducted on 50 patients of asa grade i and ii aged from 25 to 55 years and presented for laparoscopic hysterectomy. patients will be divided into two equal groups; group a control group for conventional epidural technique(n=25) and group b for 25g dural puncture epidural with 25g pencil point whitacre spinal needle (n=25). randomization will be done using computer generated number and concealed using sequentially numbered, sealed opaque envelope.


Eligibility criteria:
inclusion criteria: * asa i and ii * height(150-170 cm) exclusion criteria: * patient refusal * hypersensitivity to local anesthetic drugs * bleeding disorders and coagulopathy(platelets count less than 80000,inr less than 1.5 or therapeutic dose of anticoagulant).
study of t3 for the treatment of fibromyalgia

Conditions: Fibromyalgia

Summary: determine if t3 - the active form of thyroid hormone - is beneficial in fibromyalgia. determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using t3 (the active form of thyroid hormone) for the treatment of fibromyalgia. we specifically aim to assess the feasibility, cost, obstacles and promise of conducting a prospective controlled study in the future.


Eligibility criteria:
inclusion criteria: 1. age 18-50 2. meet american college of rheumatology criteria for fibromyalgia 3. at baseline report an average pain of 4 or more on a brief pain inventory. 4. can climb 2 flights of stairs without shortness of breath. exclusion criteria: 1. new medication change in the last 2 months 2. any cardiac disease at all 3. known thyroid disease before or after thyroid screening bloodwork 4. unstable medical or psychiatric disease. 5. known inflammatory or rheumatic disease other than fibromyalgia 6. substance abuse in the last year 7. suicidality or depression as indicated by a beck depression inventory of 30 or above 8. concomitant herbal medications 9. multiple severe medication allergies 10. the assessment of the research team that inclusion of the subject could in some way compromise the safety and validity of the study. 11. diabetes 12. smoking 13. known uncontrolled hypertension 14. known uncontrolled hypercholesterolemia
bimanual training in children with hemiplegia with lower limb and postural stimulation (habit & leg)

Conditions: Congenital Hemiplegia

Summary: a randomized control trial of "habit-ile" therapy compared with regular / conventional intervention (same amount of hours). the protocols have been developed on the basis of bimanual therapy (habit) developed at columbia university.

a randomized control trial of "habit-ile" therapy at intensive frequency contrasted with regular frequency intervention. the protocols have been developed on the basis of bimanual therapy (habit) developed at columbia university. the intervention takes place either in a 2 weeks day and night camp, either in regular/conventional intervention (1 to 5 hours a week). children of all groups will benefit from 90h of intensive treatment (children in regular frequency will be crossed over afterwards to benefit from habit-ile. both in the camp and the regular interventions, there is at least one therapist for each child.

Eligibility criteria:
inclusion criteria: * willingness to enter the research program and the testing procedures exclusion criteria: * uncontrolled epilepsy * upper limb injections in the upper limb during the last six months / or intend to receive during the training period

Keywords: bimanual training lower limb intensive rehabilitation regular rehabilitation hemiplegia
safety of pulsing heating device use on the skin

Conditions: Pain

Summary: we hope to assess the safety of a recurrent heating device for pain relief.


Eligibility criteria:
inclusion criteria: * individuals in good general health. * no known medical conditions that, in the investigator's opinion, may interfere with study participation. * subjects 18 year of age and older. exclusion criteria: * individuals who have history of acute or chronic disease that would likely interfere with or increase the risk on study participation at the discretion of the investigator. * individuals with peripheral neuropathy or a neuropathic condition that would alter their ability to sense pain. * individuals with clinically significant unstable medical disorders that would disqualify the participant at the discretion of the investigator. * individuals who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study at the discretion of the investigator. * women who are pregnant.
global utilization and registry database for improved preservation of donor livers

Conditions: Liver Diseases; Liver Dysfunction; Liver Transplant Disorder; Liver Transplant Rejection

Summary: the objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the liverguard system, as well as retrospective standard of care patients

guardian-liver is a post-market, observational registry of adult and pediatric liver transplant recipient patients whose donor liver was preserved and transported within the liverguard. the data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria. about 1000 male and female subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 20 clinical sites. candidates that fit the eligibility criteria and have had their donor liver transported with a paragonix product or a standard of care method can be enrolled. the baseline characteristics and outcomes of the two groups will be compared.

Eligibility criteria:
inclusion criteria: * donor and donor liver matched to the recipient based upon institutional medical practice * registered male or female primary liver transplant candidates exclusion criteria: * donor and donor liver that do not meet institutional clinical requirements for transplantation * living donors * pediatric recipients (under 18)
clinical features and visual prognosis of infectious endophthalmitis

Conditions: Endophthalmitis

Summary: the aim of this observational study was to retrospectively examine the clinical data of patients with infectious endophthalmitis and to analyse their clinical characteristics. the main question it aims to answer is: to find the differences between endogenous and exogenous endophthalmitis and to provide new ideas for the diagnosis and treatment of infectious endophthalmitis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with infectious endophthalmitis by specialist examination. the clinical diagnosis of endophthalmitis was established on the basis of clinical signs and symptoms, including ocular pain, loss of vision, eyelid oedema, conjunctival congestion, inflammation of the anterior chamber (flare-ups, cells, pupillary fibrin membranes, and pus accumulation in the anterior chamber), vitritis, and vitreous clouding on b-scan ultrasound. the diagnosis of infectious endophthalmitis was clarified by the aqueous vitreous pathogen detection test. exclusion criteria: * patients with incomplete medical records; non-infectious uveitis, retinal tumour disease, ocular ischaemia syndrome and other diseases with similar manifestations to endophthalmitis.

Keywords: infectious endophthalmitis endogenous endophthalmitis exogenous endophthalmitis
assessment of vivity with french clinical data related to the toric model study

Conditions: Cataract

Summary: presbyopia-correcting implant (pc-iol): acrysof iq vivity (alcon) has been evaluated in 2 large pivotal trials (us and ous trials). these tests showed that this pc-iol restored intermediate visual acuity (iva) and near visual acuity (nv a) superior to that of the reference monofocal acrysof implant. in these tests, it was demonstrated that distance visual acuity (dva) was non-inferior. however, the intermediate visual acuity for this implant in its toric version has not been evaluated.


Eligibility criteria:
inclusion criteria: * patient presenting for a request for cataract surgery in current practice: phacoemulsification followed by classic implantation of an iol with small incision size (\< 2.2mm) * calculated power of iol is between 10.0 and 30.0 diopters (d) in 0.5d steps to target emmetropia (0.0 +/- 0.5d) * patients with corneal astigmatism \> 0.5d and who can receive an implant with a toricity between t2 and t6, i.e. with astigmatism between +0.5d and +2.5d. * if both eyes have astigmatism, the eye under study will be the right eye * patient having been informed and not objecting to their participation. exclusion criteria: * pregnancy or breastfeeding while conducting the study * person under the age of 18 * history of pathologies of the anterior segment of the eye (cornea, anterior chamber, sulcus) or posterior segment of the eye (uvea, vitreous, retina) including retinal vascular occlusions, retinal detachment, peripheral retinal laser photocoagulation, amd and glaucoma * any inflammation of the anterior or posterior segment, whatever its etiology or history of disease, which may lead to an inflammatory reaction * clinically significant corneal pathology (epithelial, stromal, or endothelial that could affect visual outcome) * clinically significant severe dry eye disease that may affect visual calculations and measurements * history of refractive surgery * amblyopia or monofixation syndrome * patient at risk of zonular rupture during the phacoemulsification procedure and may affect the centering or tilt of the implant postoperatively. * irregular astigmatism (corneal topography) * any other planned eye surgery
edaravone dexborneol for treatment of hypertensive intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: pending


Eligibility criteria:
inclusion criteria: * written informed consent from the patient or legally acceptable representative * males and females * diagnose as hypertensive intracerebral hemorrhage * onset of symptoms within 6\~48 hours * position of bleeding major in basal ganglia * the sum of scores on items 5 and 6 on the nihss were \>= 2 at baseline and the total score (items 1-11) was \>=6 and \<=20 * volume of hematoma \<= 30 ml * premorbid mrs score of 0 or 1 exclusion criteria: * allergy to known study drugs or excipients * experienced stroke in latest 3 month * volume of hematoma \> 5 ml in other bleeding position * obstructive hydrocephalus * any diagnosis as other than hypertensive ich * unconsciousness * severe concurrent illness with life expectancy less than 90 days * pregnancy or breast-feeding
il37,tlymphocytes,nk cells in pathogenesis of itp

Conditions: ITP

Summary: to evaluate the role of il37 in pathogenesis of itp and to study the relation between il37,tlymphocytes,nk cells in itp

idiopathic thrombocytopenia or immune thrombocytopenia (itp) is a hematological condition which is characterized by a low platelet count of less than 100 x 109l . symptoms of itp can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) interleukin (il)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). il-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (pbmcs) (5). the major role of il-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including il-1α, il-6, tumor necrosis factor (tnf) and macrophage inflammatory protein-2. the abundance of these cytokines has been reported to increase with the silencing of endogenous il-37 in human blood cells (3,6).aberrant expression of il-37 has been observed in several inflammatory and autoimmune diseases however, the role of il-37 in itp has remained elusive. immune thrombocytopenia pathogenesis is a complicated process. t cell immune abnormalities are involved in itp pathogenesis. these abnormalities include platelet auto-antigen reactive cytotoxic t cells, abnormal numbers and functions of t regulatory cells, loss of th1/th2 balance, megakaryocyte maturation abnormalities and abnormal t cell anergy.

Eligibility criteria:
inclusion criteria: * patients with itp (moderate and sever) different age group. exclusion criteria: * patients with stroke and myocardial infarction,malignant tumors or pregnancy.
effect of cranberry and agaves extract on microbiota and intestinal health

Conditions: Endotoxemia; Metabolic Syndrome; Glucose Metabolism Disorders; Insulin Resistance

Summary: the growing prevalence of obesity and type 2 diabetes (t2d) is a major public health problem. recent studies have clearly established that the gut microbiota plays a key role in the investigator's propensity to develop obesity and associated metabolic health disorders. the gut microbiota compositions plays a decisive role in glucose metabolism and the chronic inflammatory state associated with insulin resistance. consuming prebiotic rich diet, including polyphenol and inulin rich food could help modulate favorably the gut microbiota which could lead to a reduction of endotoxemia and beneficial metabolic health effects.

it is now recognized that overweight individuals have altered microbiota which could lead to intestinal barrier defects and chronic inflammation disorders. polyphenols such as proanthocyanidins may modulate the gut microbiota thereby providing beneficial effects on metabolic health. inulin is a well known prebiotic that could stimulate growth of favorable bacteria in the gut. the overall goal is to determine the efficacy and synergy of a supplement of polyphenols from cranberry extract with or without a supplement of inulin from agaves to reduce chronic inflammation and endotoxemia and to improve glucose metabolism and insulin sensitivity by modulating microbiota of overweight human subjects with metabolic syndrome symptoms.

Eligibility criteria:
inclusion criteria: * overweight (bmi 25-39.9 kg/m2) or waist circumference ≥ 80 cm (women) and ≥94 cm (men) * fasting insulin over 60 pmol/l or fasting glucose 5.6 - 6.9 mmol/l * at least one of the following criteria: tg ≥ 1.7 mmol/l; blood pressure ≥ 130/85 mmhg; hdl \< 0,9 mmol/l; hscrp 1-10 mg/l * non-smoking * eating fruits and vegetables less then 5 portions/day exclusion criteria: * chronic disease * taking drugs or natural health products that could affect glucose or lipid metabolism * taking anti-inflammatory, antiacids * taking pre or probiotics * inflammatory bowel disease * antibiotics in the past 3 months * allergy or intolerance to cranberries or agaves * major surgery in the past 3 months